Page 5 - Quick Inventory News Today

The addition of fluoxetine to CBT did not further reduce depressive symptoms in young people with moderate-to-severe depression.

Investegate announcements from COMPASS Pathways, COMPASS Pathways announces further positive results from groundbreaking phase IIb trial of investigational COMP360 psilocybin therapy for treatment-resistant depression

- Positive topline results validated by additional analyses - Patient improvements beyond reduction of depression symptoms - Further insights into timing and circumstance of adverse events demonstrate

(0) Study concludes that psilocybin findings should be explored further in larger studies London, UK, April 15, 2021(NEJM) yesterday, which showed signals of positive activity in COMP360 psilocybin compared with the standard antidepressant escitalopram, for major depressive disorder (MDD). The study was designed and conducted by a research team at Imperial College London, using COMPASSs COMP360 psilocybin. This was an exploratory, randomised, double-blind clinical study. Its aim was to compar...

Press release content from Globe Newswire. The AP news staff was not involved in its creation. New England Journal of Medicine publishes exploratory study showing signals of positive ... COMPASS Pathfinder Ltd.April 15, 2021 GMT London, UK, April 15, 2021 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, welcomed a study published in the  New England Journ...

New England Journal of Medicine publishes exploratory study showing signals of positive activity in COMP360 psilocybin compared with escitalopram for major depressive disorder COMPASS Pathways plc a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, welcomed a study published in the New England Journal of Medicine yesterday, which showed signals of positive activity in COMP360 psilocybin compared with the standard antidepressant es...

Scientific American Psilocybin Therapy May Work as Well as Common Antidepressant For the first time, a randomized controlled trial shows the psychedelic offers potent, if short-term, relief in comparison with an SSRI Print Psilocybin, the active ingredient in “magic mushrooms,” may provide relief from depression symptoms that is equivalent to, or better than, an SSRI antidepressant. Credit: Getty Images Advertisement The first randomized controlled trial to compare the illicit psychedelic p...

email article Psilocybin -- "magic mushrooms" -- failed to improve symptoms of depression over a selective serotonin reuptake inhibitor (SSRI) in a 59-patient phase II trial, though the studys leaders are not ready to give up on the hallucinogen. At 6 weeks, psilocybin did not have a significantly greater effect on symptoms of moderate-to-severe major depressive disorder compared with the SSRI escitalopram (Lexapro), as measured by mean change from baseline on the 16-item Quick Invent...

Mount Sinai Researchers from the Icahn School of Medicine at Mount Sinai have identified a drug that works against depression by a completely different mechanism than existing treatments. Their study showed that ezogabine (also known as retigabine), a drug that opens KCNQ2/3 type of potassium channels in the brain, is associated with significant improvements in depressive symptoms and anhedonia in patients with depression. Anhedonia is the reduced ability to experience pleasure or lack of react...

Landmark heart study reveals new insights about risk factors for depression Recently published UT Southwestern research reveals new insights about risk factors for depression based on data from a landmark longitudinal study focused on heart disease. One study, published in the Journal of Clinical Psychiatry, shows a link between an inflammatory molecule in the blood and a persons likelihood of depressive symptoms. The other study, in the journal Maturitas, indicates which symptoms of menopaus...